Anixa Biosciences Inc ANIX
Biosciences, Inc. is a biotechnology company developing therapies and vaccines that are focused on critical unmet needs in oncology.
Our therapeutics program consists of the development of liraltagene autoleucel ("lira-cel"), a chimeric endocrine receptor-T
cell therapy, which is a novel form of chimeric antigen receptor-T cell ("CAR-T") technology, initially focused on treating
ovarian cancer, that is being developed at our subsidiary, Certainty Therapeutics, Inc. ("Certainty"). Our vaccine programs
Last close
2.99
2026-10-23
Market cap
$101.7M
2026-04-30 share count
52-week range
2.32 - 5.46
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.34
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $210.0K | $210.0K | — | $512.0K | — | $250.0K | $1.1M | $362.5K | $300.0K |
| R&D | $5.1M | $6.4M | $4.8M | $6.7M | $6.2M | $4.4M | $5.5M | $6.8M | $1.6M | $1.6M |
| SG&A | $6.6M | $7.4M | $6.3M | $7.2M | $7.1M | $5.6M | $5.7M | $6.9M | $4.4M | $2.7M |
| Total operating expenses | $11.7M | $13.8M | $11.2M | $13.9M | $13.6M | $10.0M | $12.1M | $15.4M | $6.4M | $4.8M |
| Operating income | -$11.7M | -$13.8M | -$11.0M | -$13.9M | -$13.1M | -$10.0M | -$11.9M | -$14.3M | -$6.1M | -$4.5M |
| Interest expense | — | — | — | — | — | — | — | — | $500.5K | $519.9K |
| Pre-tax income | — | — | — | — | — | — | -$11.8M | -$14.2M | -$5.0M | -$5.0M |
| Net income | -$10.9M | -$12.6M | -$9.8M | -$13.6M | -$13.0M | -$10.0M | -$11.6M | -$14.2M | -$5.0M | -$5.0M |
| EPS, basic | -0.34 | -0.39 | -0.32 | 0.45 | -0.45 | — | — | — | — | — |
| EPS, diluted | -0.34 | -0.39 | -0.32 | 0.45 | -0.45 | -0.45 | -0.59 | -0.79 | -0.58 | -0.57 |
| Shares, diluted (wtd. avg.) | 32,454 | 31,898 | 30,980 | 30,374 | 28.6M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $1.2M | $1.3M | $915.0K | $12.4M | $29.1M | $6.4M | $3.5M | $3.1M | $3.3M | $2.5M |
| Short-term investments | $13.9M | $18.7M | $22.9M | $17.3M | $6.6M | $2.6M | $2.4M | $2.0M | $3.5M | $750.0K |
| Receivables | — | $173.0K | $270.0K | $46.0K | — | $2.2K | $66.5K | $307.0K | — | — |
| Total current assets | $15.9M | $21.4M | $25.4M | $30.2M | $36.0M | $9.4M | $6.1M | $5.5M | $7.0M | $3.4M |
| Property, plant and equipment | — | — | — | — | — | — | $200.6K | $72.7K | $52.7K | $156.6K |
| Total assets | $16.1M | $21.6M | $25.5M | $30.4M | $36.3M | $9.5M | $6.3M | $6.4M | $8.8M | $5.6M |
| Accounts payable | $165.0K | $525.0K | $206.0K | $265.0K | $136.0K | $232.4K | $585.8K | $582.0K | $480.3K | $373.2K |
| Total current liabilities | $2.0M | $2.5M | $2.0M | $2.0M | $1.3M | $1.2M | $1.5M | $1.3M | $889.5K | $468.8K |
| Total liabilities | $2.1M | $2.7M | $2.2M | $2.2M | $1.5M | $1.2M | — | — | $889.5K | $4.6M |
| Retained earnings | -$251.7M | -$240.8M | -$228.2M | -$218.4M | -$204.8M | -$191.8M | -$181.8M | -$170.2M | -$156.2M | -$151.2M |
| Total equity | $15.2M | $20.0M | $23.4M | $28.2M | $34.8M | $8.3M | $4.8M | $5.2M | $7.9M | $987.5K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.2M | -$7.3M | -$6.2M | -$6.5M | -$4.9M | -$6.2M | -$4.7M | -$4.3M | -$3.8M | -$3.4M |
| Depreciation and amortisation | — | — | — | — | — | $38.3K | $47.6K | $18.4K | — | — |
| Stock-based compensation | $3.7M | $4.4M | $4.4M | $6.0M | $7.5M | $3.9M | — | — | — | — |
| Capital expenditure | — | — | — | — | — | $15.8K | $175.5K | $38.4K | $30.2K | $146.5K |
| Investing cash flow | $4.9M | $4.3M | -$5.6M | -$10.7M | -$3.9M | -$305.8K | -$525.5K | $1.5M | -$2.7M | $1.5M |
| Financing cash flow | $2.3M | $3.4M | $366.0K | $452.0K | $31.6M | $9.4M | $5.7M | $2.5M | $7.4M | -$2.7K |
| Buybacks | — | $6.0K | — | — | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-001845.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $300.0K | $362.5K | $1.1M | $250.0K | — | $512.0K | — | $210.0K | $210.0K | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$5.0M | -$5.0M | -$14.2M | -$11.6M | -$10.0M | -$13.0M | -$13.6M | -$9.8M | -$12.6M | -$10.9M |
Recent filings and events
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Regulation FD disclosure Item 7.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Regulation FD disclosure Item 7.01
- Shareholder vote Item 5.07
- Regulation FD disclosure Item 7.01
- Annual report filed Form 10-K
- Regulation FD disclosure Item 7.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Regulation FD disclosure Item 7.01
- Shareholder vote Item 5.07
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |